Literature DB >> 29675587

A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of "High"-grade Well-Differentiated Neuroendocrine Neoplasm.

Elia Guadagno1, Gaetano Luglio2, Alessandro Iacobelli3, Giorgio Borrelli3, Antonio Castaldi2, Gaetano De Rosa3, Marialaura Del Basso De Caro3.   

Abstract

Grade 3 neuroendocrine tumor (NET G3) is a rare new entity that has recently been introduced in the classification of neuroendocrine neoplasms of the pancreas. It is a well-differentiated form, with a high proliferative activity (Ki67 > 20%), and it represents a category whose prognosis is intermediate between NET G2 and poorly differentiated neuroendocrine carcinoma (NEC G3). In sites other than the pancreas, this new category is by far less coded. Herein is reported a case of NET G3 of the stomach, the 13th described in literature. The patient was a 71-year-old man with a mass in the gastric fundus. Histological examination revealed a neuroendocrine tumor that was mostly composed by areas with conventional well-differentiated features and intermediate proliferative rate (< 20 mitoses/10 HPFs and 7% Ki67); part of the tumor was characterized by increased nuclear atypia, a confluent growth pattern, intermediate mitotic activity, and high Ki67 value (25%). The tumor was studied immunohistochemically and molecularly, and the only alteration that came out was MEN1 gene mutation (Lau584SerfsTer5) in both the high- and low-grade components. According to the actual classification of gastric neuroendocrine neoplasms, this case is labeled as NEC G3 but it should be named NET G3, with a much better prognosis than the former. Overall, both morphological pattern and the Ki67 value should be mentioned in the histological report in cases of high-grade neuroendocrine neoplasms because of its clinical significance in defining the prognosis and for new potential therapeutic approaches.

Entities:  

Keywords:  G3; Heterogeneity; Morphology; Neuroendocrine

Mesh:

Year:  2018        PMID: 29675587     DOI: 10.1007/s12022-018-9528-5

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  15 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

Review 3.  Immunohistochemical evaluation of mismatch repair proteins in colorectal carcinoma: the AIFEG/GIPAD proposal.

Authors:  A Remo; M Fassan; G Lanza
Journal:  Pathologica       Date:  2016-09

4.  Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.

Authors:  M Heetfeld; C N Chougnet; I H Olsen; A Rinke; I Borbath; G Crespo; J Barriuso; M Pavel; D O'Toole; T Walter
Journal:  Endocr Relat Cancer       Date:  2015-06-25       Impact factor: 5.678

5.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  K Öberg; U Knigge; D Kwekkeboom; A Perren
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

6.  Correction: Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors: 
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

Review 7.  The challenge of classifying poorly differentiated tumours in the lung.

Authors:  William A H Wallace
Journal:  Histopathology       Date:  2009-01       Impact factor: 5.087

8.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

9.  The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.

Authors:  Massimo Milione; Patrick Maisonneuve; Francesca Spada; Alessio Pellegrinelli; Paola Spaggiari; Luca Albarello; Eleonora Pisa; Massimo Barberis; Alessandro Vanoli; Roberto Buzzoni; Sara Pusceddu; Laura Concas; Fausto Sessa; Enrico Solcia; Carlo Capella; Nicola Fazio; Stefano La Rosa
Journal:  Neuroendocrinology       Date:  2016-03-05       Impact factor: 4.914

10.  Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Authors:  Fritz-Line Vélayoudom-Céphise; Pierre Duvillard; Lydia Foucan; Julien Hadoux; Cecile N Chougnet; Sophie Leboulleux; David Malka; Joël Guigay; Diane Goere; Thierry Debaere; Caroline Caramella; Martin Schlumberger; David Planchard; Dominique Elias; Michel Ducreux; Jean-Yves Scoazec; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

View more
  3 in total

Review 1.  Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.

Authors:  Sylvia L Asa; Stefano La Rosa; Olca Basturk; Volkan Adsay; Marianna Minnetti; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2021-01-18       Impact factor: 3.943

Review 2.  Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Authors:  Silvia Uccella; Stefano La Rosa; Jasna Metovic; Deborah Marchiori; Jean-Yves Scoazec; Marco Volante; Ozgur Mete; Mauro Papotti
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

3.  The Histopathological Types and Distribution Characteristics of Gastric Mixed Tumors.

Authors:  Fang-Heng Zhu; Yang-Kun Wang; Jun-Ling Zhou; Nian-Long Meng; Yue Wang; Bo Jiang; Su-Nan Wang
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.